Skip to main content
Premium Trial:

Request an Annual Quote

Joslin Diabetes Center to Use Metabolon Profiling Technology in Studies

NEW YORK (GenomeWeb News) – The Joslin Diabetes Center will use Metabolon’s biochemical profiling technology in human clinical and animal studies of insulin resistance and type 2 diabetes, Metabolon said today.
Research Triangle Park, NC-based Metabolon also will assess the translatability of its human insulin resistance biomarkers when conducting the Joslin diabetic animal model studies. In addition, the partners will collaborate on further validation studies of human biochemical markers of insulin resistance.
Metabolon noted that it is working with academic centers around the world on developing a diagnostic test for insulin resistance, a condition which the firm said affects more than a quarter of the US adult population.
“Mechanism-based biomarker diagnostics are a much-needed tool in the identification and management of patients at risk for type 2 diabetes and cardiovascular disease," Metabolon CEO John Ryals said in a statement. "Our partnership with Joslin gives us the opportunity to further validate the biomarkers of insulin resistance that we have identified."
Financial and other terms of the collaboration were not disclosed.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.